Secondary Objectives. The secondary objectives of each study are to evaluate: ▪ The safety of discontinuing vs. continuing hypertonic saline (Study A) or dornase alfa (Study B) ▪ The effect of discontinuing vs. continuing hypertonic saline (Study A) or dornase alfa (Study B) on lung clearance index (LCI) ▪ The effect of discontinuing vs. continuing hypertonic saline (Study A) or dornase alfa (Study B) on other clinical outcomes (e.g., antibiotic events, pulmonary exacerbations, and patient reported outcomes)
Appears in 3 contracts
Sources: Protocol Agreement, Protocol Agreement, Protocol Agreement